Skip to main content

Table 2 Improvement from baseline after one year treatment with etanercept or adalimumab

From: Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers

  Pooled data Etanercept Adalimumab
  Adjusted mean changes (95% CI) P-value Adjusted mean changes (95% CI) P-value Adjusted mean changes (95% CI) P-value
  <4 years ≥4 years   <4 years ≥4 years   <4 years ≥4 years  
BASDAI 3.2 (2.7, 3.7) 1.7 (1.1, 2.2) 0.001 3.1 (2.6, 3.6) 1.8 (1.1, 2.6) 0.008 3.2 (2.2, 4.3) 1.6 (0.9, 2.3) 0.02
BASFI 2.4 (2, 2.9) 1.2 (0.7, 1.6) 0.001 2.4 (1.9, 2.8) 1.2 (0.5, 1.8) 0.006 2.5 (1.5, 3.5) 1.3 (0.5, 2) 0.06
BASMI 0.3 (0, 0.6) −0.1 (−0.4, 0.2) 0.09 0.4 (0.1, 0.7) −0.02 (−0.5, 0.4) 0.16 0.02 (−0.6, 0.6) −0.1 (−0.5, 0.3) 0.74
ASDAS 1.6 (1.4, 1.8) 0.9 (0.7, 1.1) 0.001 1.5 (1.3, 1.8) 1.1 (0.8, 1.4) 0.04 1.7 (1.2, 2.1) 0.8 (0.5, 1.1) 0.003
CRP* 1.6 (1.5, 2) 1.6 (1.4, 1.8) 0.72 1.5 (1.4, 1.8) 1.6 (1.4, 2.0) 0.60 2.2 (1.6, 3.0) 1.5 (1.2, 1.8) 0.06
MRI SIJ 3.5 (2.9, 4.1) 3 (2.3, 3.6) 0.28 3.9 (3.3, 4.6) 3.7 (2.8, 4.6) 0.71 7.0 (3.8, 10.1) 2.7 (0.7, 4.7) 0.04
  1. *Log-transformed CRP results were back transformed; p-value <0.05 was taken to indicate statistically significant differences between two groups; adjusted mean changes from baseline under treatment with etanercept or adalimumab (95% CI). Outcome differences were adjusted for baseline status (see Methods). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein in mg/l; MRI, magnetic resonance imaging; SIJ sacroiliac joint.